Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Prolastin, Prolastin-C Market Size Outlook: How Fast Will Revenue Grow Through 2030?
Growth during the historic period was driven by the approval for alpha-1 antitrypsin deficiency, demonstrated clinical effectiveness in shielding the lungs, increased adoption among pulmonology specialists, a scarcity of therapeutic options, and the accessibility of plasma-derived proteins.
The expansion projected for the forecast timeframe is driven by higher rates of genetic screening, increased public knowledge regarding AAT deficiency, a growing number of specialized care facilities, a greater prevalence of respiratory illnesses, and improved consistency in long-term treatment adherence. Key developments shaping this period involve the wider application of alpha-1 replacement therapy, broader implementation of sustained lung protection strategies, more frequent detection of AAT deficiency, the integration of augmentation therapy within hospital settings, and a strong emphasis on halting disease advancement.
Download A Free Sample Report For Comprehensive Market Insights:
Prolastin, Prolastin-C Market Opportunity Drivers: What Is Creating New Revenue Potential?
The anticipated rise in respiratory infection cases is poised to drive the expansion of the prolastin and prolastin-C market. Respiratory infections are defined as illnesses affecting the respiratory system, encompassing the nose, throat, airways, and lungs, and are triggered by various pathogens including viruses, bacteria, fungi, or other microorganisms. This prevalence is fueled by emerging viral strains, seasonal shifts, compromised immune function, and is further intensified by environmental pollution as well as heightened human movement. As forms of alpha-1 antitrypsin (AAT) replacement therapy, Prolastin and Prolastin-C are used to control respiratory conditions—especially COPD linked to alpha-1 antitrypsin deficiency—by restoring the deficient AAT protein, thereby decreasing lung inflammation, safeguarding tissues from protease-driven impairment, and boosting lung performance as well as overall respiratory health for individuals impacted by this hereditary disease. To illustrate, the National Asthma Council, a non-profit organization based in Australia, reported in October 2024 that 474 asthma-related fatalities were recorded in Australia in 2023, with 325 involving females and 149 males. This number closely matches the 473 asthma-related deaths from 2022, demonstrating a steady pattern in asthma mortality across those two years. Consequently, the growing frequency of respiratory infections is fueling progress in the prolastin, prolastin-C market.
Prolastin, Prolastin-C Market Driver: Rising Research And Development Expenditure Driving Growth In The Prolastin-C Market
Growth in the prolastin and prolastin-C market is expected to be significantly propelled by mounting research and development expenditure. Research and development (R&D) encompasses the methodical and structured endeavors carried out by businesses, entities, or researchers to acquire novel insights, devise groundbreaking products, or refine current processes and services. This spending is on the rise due to a growing necessity for innovation, technological progress, and the creation of novel products and treatments within competitive markets. Heightened R&D investment positively influences Prolastin and prolastin-C by facilitating sophisticated clinical studies, boosting their effectiveness, and speeding up the creation of better formulations or dosing plans to achieve superior patient results. For example, data from February 2025 by the National Center for Science and Engineering Statistics (NCSES), a U.S. government statistical body, indicated that American research and development outlays climbed from $892 billion in 2022 to $940 billion in 2023, a $48 billion rise. Thus, the surge in research and development expenditure is promoting market growth for prolastin and prolastin-C.
Prolastin, Prolastin-C Market Segments: Where Are The Largest Growth Opportunities?
The prolastin, prolastin-c market covered in this report is segmented –
1) By Type: 20ml, 40ml
2) By Indication: Alpha-1 Antitrypsin Deficiency, Respiratory Health, Chronic Lung Disease, Genetic Disorders
3) By Application: Hospital, Pharmacy
Prolastin, Prolastin-C Market Innovation Trends Driving Future Development
Key players in the peolastin and prolastin-C market are actively investing in clinical trials to thoroughly examine the safety and efficacy of their pharmaceutical products. These clinical trials involve systematic investigations on human participants to determine the safety, effectiveness, and possible adverse effects of new therapies, medications, or medical devices. A notable example is Grifols SA, a pharmaceutical company based in Spain, which achieved its enrollment target of 339 patients in July 2023 for the SPARTA phase 3 clinical trial, formally known as the Study of ProlAstin-c Randomized Therapy with Alpha-1 Augmentation. The primary objective of this study is to assess whether patients diagnosed with emphysema resulting from alpha-1-antitrypsin (AAT) deficiency exhibit a reduced rate of lung tissue deterioration when receiving weekly infusions of Grifols Prolastin-C at two distinct dosage levels. This investigation is designed to measure the drug’s effectiveness in slowing emphysema progression among individuals with alpha-1 antitrypsin deficiency (AATD) by increasing AAT protein levels through weekly administration of two active doses, specifically 60 and 120 mg per kilogram, in comparison with a placebo group.
Prolastin, Prolastin-C Market Major Participants And Competitive Dynamics
Major companies operating in the prolastin, prolastin-c market are Grifols SA
Access The Complete Prolastin, Prolastin-C Market Report:
Prolastin, Prolastin-C Market Largest Region By Revenue And Market Share
North America was the largest region in the prolastin or prolastin-C market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prolastin, prolastin-c market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model